| Full text | |
| Author(s): Show less - |
de Sousa Marques, Heloisa Helena
[1]
;
Badue Pereira, Maria Fernanda
[1]
;
dos Santos, Angelica Carreira
[1]
;
Fink, Thais Toledo
[1]
;
Yoshino de Paula, Camila Sanson
[1]
;
Litvinov, Nadia
[1]
;
Schvartsman, Claudio
[1]
;
Delgado, Artur Figueiredo
[1]
;
Bento Cicaroni Gibelli, Maria Augusta
[1]
;
de Carvalhol, Werther Brunow
[1]
;
Odone Filho, Vicente
[1]
;
Tannuri, Uenis
[1]
;
Carneiro-Sampaio, Magda
[1]
;
Grisi, Sandra
[1]
;
da Silva Duarte, Alberto Jose
[1]
;
Antonangelo, Leila
[1]
;
Vieira Francisco, Rossana Pucineli
[1]
;
Okay, Thelma Suely
[1]
;
Batisttella, Linamara Rizzo
[1]
;
Ribeiro de Carvalho, Carlos Roberto
[1]
;
Maria Brentani, Alexandra Valeria
[1]
;
Silva, Clovis Artur
[1]
;
Grp, HC-FMUSP Pediat COVID Study
Total Authors: 23
|
| Affiliation: | [1] Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP - Brazil
Total Affiliations: 1
|
| Document type: | Journal article |
| Source: | Clinics; v. 76, 2021. |
| Web of Science Citations: | 1 |
| Abstract | |
OBJECTIVES: To compare demographic/clinical/laboratory/treatments and outcomes among children and adolescents with laboratory-confirmed coronavirus disease 2019 (COVID-19). METHODS: This was a cross-sectional study that included patients diagnosed with pediatric COVID-19 (aged <18 years) between April 11, 2020 and April 22, 2021. During this period, 102/5,951 (1.7%) of all admissions occurred in neonates, children, and adolescents. Furthermore, 3,962 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection samples were processed in patients aged <18 years, and laboratory-confirmed COVID-19 occurred in 155 (4%) inpatients and outpatients. Six/155 pediatric patients were excluded from the study. Therefore, the final group included 149 children and adolescents (n=97 inpatients and 52 outpatients) with positive SARS-CoV-2 results. RESULTS: The frequencies of sore throat, anosmia, dysgeusia, headache, myalgia, nausea, lymphopenia, pre-existing chronic conditions, immunosuppressive conditions, and autoimmune diseases were significantly reduced in children and adolescents (p<0.05). Likewise, the frequencies of enoxaparin use (p=0.037), current immunosuppressant use (p=0.008), vasoactive agents (p=0.045), arterial hypotension (p<0.001), and shock (p=0.024) were significantly lower in children than in adolescents. Logistic regression analysis showed that adolescents with laboratory-confirmed COVID-19 had increased odds ratios (ORs) for sore throat (OR 13.054; 95% confidence interval [CI] 2.750-61.977; p=0.001), nausea (OR 8.875; 95% CI 1.660-47.446; p=0.011), and lymphopenia (OR 3.575; 95% CI 1.355-9.430; p=0.010), but also had less hospitalizations (OR 0.355; 95% CI 0.138-0.916; p=0.032). The additional logistic regression analysis on patients with preexisting chronic conditions (n=108) showed that death as an outcome was significantly associated with pediatric severe acute respiratory syndrome (SARS) (OR 22.300; 95% CI 2.341-212.421; p=0.007) and multisystem inflammatory syndrome in children (MIS-C) (OR 11.261; 95% CI 1.189-106. 581; p=0.035). CONCLUSIONS: Half of the laboratory-confirmed COVID-19 cases occurred in adolescents. Individuals belonging to this age group had an acute systemic involvement of SARS-CoV-2 infection. Pediatric SARS and MIS-C were the most important factors associated with the mortality rate in pediatric chronic conditions with COVID-19. (AU) | |
| FAPESP's process: | 15/03756-4 - Assessment of relevance of blood levels of drugs in the monitoring rheumatic autoimmune diseases: safety, effectiveness and adherence to therapy |
| Grantee: | Eloisa Silva Dutra de Oliveira Bonfá |
| Support Opportunities: | Research Projects - Thematic Grants |